An immunochemical analysis of mdm2 expression in human breast cancer and the identification of a growth-regulated cross-reacting species p170

Journal of Pathology

Volumn 186, Issue 3, 1998, Pages 254-261

  O'Neill, Mary ^a   Campbell, Sandra J ^a   Save, Vicki ^a   Thompson, Alastair M ^a   Hall, Peter A ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

Breast cancer; Immunochemistry; mdm2; p53

Indexed keywords

DNA; ISOPROTEIN; NUCLEAR PROTEIN; PHYTOHEMAGGLUTININ; PROTEIN P53;

ARTICLE; BREAST CARCINOMA; CONTROLLED STUDY; CROSS REACTION; DNA DAMAGE; FEMALE; GENE OVEREXPRESSION; GROWTH REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCHEMISTRY; MAJOR CLINICAL STUDY; MUTATION; NULL CELL; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; ULTRAVIOLET RADIATION;

ADENOCARCINOMA; BLOTTING, SOUTHERN; BLOTTING, WESTERN; BREAST NEOPLASMS; ELECTROPHORESIS, POLYACRYLAMIDE GEL; FEMALE; HUMANS; IMMUNOBLOTTING; LOSS OF HETEROZYGOSITY; MUTATION; NEOPLASM PROTEINS; NUCLEAR PROTEINS; PHENOTYPE; PRECIPITIN TESTS; PROTEIN ISOFORMS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; SENSITIVITY AND SPECIFICITY; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0031728614     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9896(1998110)186:3<254::AID-PATH185>3.0.CO;2-U     Document Type: Article

References (57)

1. Piette J, Neel H, Marechal V. mdm2: keeping p53 under control. Oncogens 1997; 15(9): 1001-1010.
2. Snyder LC, Trusko SP, Freeman N, Eshleman JR, Fakharzadeh SS, George DL. A gene amplified in a transformed mouse cell line undergoes complex transcriptional processing and encodes a nuclear protein. J Biol Chem 1988: 263: 17 150-17 158.
3. Fakharzadeh SS, Trusko SP, George DL. Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line. EMBO J 1991; 10: 1565-1569.
4. Momand J, Zambetti GP, Olson DC, George D, Levine AJ. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 1992; 69: 1237-1245.
5. Chen J. Marechal V, Levine AJ. Mapping of the p53 and mdm-2 interaction domains. Mol Cell Biol 1993; 13(7): 4107-4114.
6. Picksley SM, Vojtesek B, Sparks A, Lane DP. Immunochemical analysis of the interaction of p53 with MDM2 - fine mapping of the MDM2 binding site on p53 using synthetic peptides. Oncogene 1994; 9: 2523-2529.
7. Bottger A, Bottger V, Garcia-Echeverria C, el al. Molecular characterization of the hdm2-p53 interaction. J Mol Biol 1997; 269(5): 744-756.
8. Kussie PH, Gorina S, Marechal V, et al. Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science 1996; 274: 948-953.
9. Haupt Y, Maya R, Kazaz A, Oren M. mdm2 promotes the rapid degradation of p53. Nature 1997; 387: 296-299.
10. Kubbutat MH, Jones SN, Vousden KH. Regulation of p53 stability by mdm2. Nature 1997; 387: 299-303.
11. Blaydes JP, Gire V, Rowson JM, Wynford-Thomas D. Tolerance of high levels of wild-type p53 in transformed epithelial cells dependent on auto-regulation by mdm-2. Oncogene 1997; 14(15): 1859-1868.
12. Lane DP, Hall PA. MDM2: arbiter of p53's destruction. Trends in Biochemical Sciences 1997; 22: 372-374.
13. Midgley CA, Lane DP. p53 protein stability in tumour cells is not determined by mutation but is dependent on mdm2 binding. Oncogene 1997; 15: 1179-1189.
14. Shieh SY, Ikeda M, Taya Y, Prives C. DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell 1997; 91: 325-334.
15. Siliciano JD, Canman CE, Taya Y, Sakaguchi K, Appella E, Kastan MB. DNA damage induces phosphorylation of the amino terminus of p53. Genes Dev 1997; 11: 3471-3481.
16. Mayo LD, Turchi JJ, Berberich SJ. mdm-2 phosphorylation by DNA-dependent protein kinase prevents interaction with p53. Cancer Res 1997; 57: 5013-5016.
17. Elenbaas B, Dobbelstein M, Roth J, Shenk T, Levine AJ. The MDM2 oncoprotein binds specifically to RNA through its RING finger domain. Mol Med 1996; 2: 439-451.
18. Roth J, Dobbelstein M, Freedman DA, Shenk T, Levine AJ. Nucleocytoplasmic shuttling of the hdm2 oncoprotein regulates the levels of the p53 protein via a pathway used by the human immunodeficiency virus rev protein. EMBO J 1998; 17: 554-564.
19. Moll UM, Ostermeyer AG, Haladay R, Winkfield B, Frazier M, Zambetti G. Cytoplasmic sequestration of wild-type p53 protein impairs the G1 checkpoint after DNA damage. Moll Cell Biol 1996; 16: 1126-1137.
20. Martin K. Trouche D, Hagemeier C, Sorensen TS, La Thangue NB, Kouzarides T. Stimulation of E2F1/DP1 transcriptional activity by MDM2 oncoprotein. Nature 1995; 375: 691-694.
21. Xiao ZX, Chen J, Levine AJ, et al. Interaction between the retinoblastoma protein and the oncoprotein MDM2. Nature 1995; 375: 694-698.
22. ARF. interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell 1998; 93: 713-723.
23. Zhang Y, Xiong Y, Yarbrough WG. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumour suppression pathways. Cell 1998; 92: 725-734.
24. Thut CJ, Goodrich JA, Tjian R. Repression of p53-mediated transcription by MDM2: a dual mechanism. Genes Dev 1997; 11: 1974-1986.
25. Shaulian E, Resnitzky D, Shifman O, et al. Induction of Mdm2 and enhancement of cell survival by bFGF. Oncogene 1997; 15: 2717-2725.
26. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997; 88: 323-331.
27. Ko LJ, Prives C. p53: puzzle and paradigm. Genes Dev 1996; 10: 1054-1072.
28. Soussi T. hhtp://perso.curie.fr/Thierry. Soussi/p53_mutation_in_breast. html.
29. Sjogren S, Inganas M, Norberg T, et al. The p53 gene in breast cancer: prognostic value of complementary DNA sequencing versus immunohistochemistry. J Natl Cancer lnst 1996; 88: 173-182.
30. Oliner JD, Kinzler KW, Meltzer PS, George DL, Vogelstein B. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 1992; 358: 80-83.
31. Courjal F, Cum M, Rodriguez C, et al. DNA amplifications at 20q 13 and MDM2 define distinct subsets of evolved breast and ovarian tumours. Br J Cancer 1996; 74: 1984-1989.
32. Quesnel B, Preudhomme C, Fournier J, Fenaux P, Peyrat JP. MDM2 gene amplification in human breast cancer. Eur J Cancer 1994; 30: 982-984.
33. Marchetti A, Buttitta F, Girlando S, et al. mdm2 gene alterations and mdm2 protein expression in breast carcinomas. J Pathol 1995; 175: 31-38.
34. McCann AH, Kirley A, Carney DN, et al. Amplification of the MDM2 gene in human breast cancer and its association with MDM2 and p53 protein status. Br J Cancer 1995; 71: 981-985.
35. Lundgren K, Montes de Oca Luna R, McNeill YB, et al Targeted expression of MDM2 uncouples S phase from mitosis and inhibits mammary gland development independent of p53. Genes Dev 1997; 11: 714-725.
36. Thompson AM, Anderson TJ, Condie A, et al. p53 allele losses, mutations and expression in breast cancer and their relationship to clinico-pathological parameters. Int J Cancer 1992; 50: 528-532.
37. Thompson AM, Crichton DN, Elton RA, Clay MF, Chetty U, Steel CM. Allelic imbalance at chromosome 17p13.3 (YNZ22) in breast cancer is independent of p53 mutation or p53 overexpression and is associated with poor prognosis at medium-term follow-up. Br J Cancer 1998; 77: 797-800.
38. Bradford M. A rapid and sensitive method for quantitation of microgram quantities of protein utilising the principle of protein-dye binding. Anal Biochem 1976; 72: 248.
39. Harlow E, Lane DP, Antibodies: A Laboratory Manual. New York: Cold Spring Harbor Laboratory Press, 1988.
40. De Oca Luna RM, Wagner DS, Lozano G. Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature 1995; 378: 203-206.
41. Dowell SP, Hall PA. The p53 tumour suppressor gene and tumour prognosis: is there a relationship? J Pathol 1995; 177: 221-224.
42. Tsuda H, Hirohashi S. Association among p53 gene mutation, nuclear accumulation of the p53 protein and aggressive phenotypes in breast cancer. Int J Cancer 1994; 57: 4498-4503.
43. Sheikh MS, Shao ZM, Hussain A, Fontana JA. The p53-binding protein MDM2 gene is differentially expressed in human breast carcinoma. Cancer Res 1993; 53: 3226-3228.
44. Gudas JM, Nguyen H, Klein RC, Katayose D, Seth P, Cowan KH. Differential expression of multiple MDM2 messenger RNAs and proteins in normal and tumorigenic breast epithelial cells. Clinical Cancer Research 1995; 1: 71-80.
45. Bueso-Ramos CE, Manshouri T, Haidar MA, et al. Abnormal expression of MDM-2 in breast carcinomas. Breast Cancer Res Treat 1996; 37(2): 179-188.
46. Giannikaki E, Kouvidou C, Tzardi M, et al. p53 protein expression in breast carcinomas. Comparative study with the wild type p53 induced proteins mdm2 and p21/waf1. Anticancer Res 1997; 17: 2123-2127.
47. Gunther T, Schneider-Stock R, Rys J, Niezabitowski A, Roessner A. p53 gene mutations and expression of p53 and mdm2 proteins in invasive breast carcinoma. A comparative analysis with clinico-pathological factors. J Cancer Res Clin Oncol 1997; 123: 388-394.
48. Jiang M, Shao ZM, Wu J, el al. p21/waf1/cipl and mdm-2 expression in breast carcinoma patients as related to prognosis. Int J Cancer 1997; 74: 529-534.
49. Schlott T, Reimer S, Jahns A, et al. Point mutations and nucleotide insertions in the MDM2 zinc finger structure of human tumours. J Pathol 1997; 182: 54-61.
50. Gorgoulis VG, Zoumpourlis V, Rassidakis GZ, et al. A molecular and immunohistochemical study of the MDM2 protein isoforms and p53 gene product in bronchogenic carcinoma. J Pathol 1996; 180: 129-137.
51. Chen L, Marechal V, Moreau J, Levine AJ, Chen J. Proteolytic cleavage of the mdm2 oncoprotein during apoptosis. J Biol Chem 1997; 272(36): 22 966-22 973.
52. Erhardt P, Tomaselli KJ, Cooper GM. Identification of the MDM2 oncoprotein as a substrate for CPP32-like apoptotic proteases. J Biol Chem 1997; 272: 15 049-15 052.
53. Midgley CA, Owens B, Briscoe CV, Thomas DB, Lane DP, Hall PA. Coupling between gamma irradiation. p53 induction and the apoptotic response depends upon cell type in vivo. J Cell Science 1995; 108: 1843-1841.
54. Sigalas I, Calvert AH, Anderson JJ, Neal DE, Lunec J. Alternatively spliced mdm2 transcripts with loss of p53 binding domain sequences: transforming ability and frequent detection in human cancer. Nature Med 1996; 2(8): 912-917.
55. Ibrahim AP, Gallimore PH, Grand RJ. The expression of MDM2 and other p53-regulated proteins in the tissues of the developing rat. Biochim Biophys Acta 1997; 1350: 306-316.
56. Matsumoto R, Tada M, Nozaki M, Zhang CL, Sawamura Y, Abe H. Short alternative splice transcripts of the mdm2 oncogene correlate to malignancy in human astrocytic neoplasms. Cancer Res 1998; 58(4): 609-613.
57. Altschul SF, Madden TL, Schaffer AA, et al. Gapped BLAST and PSI-BLAST; a new generation of protein database search programs. Nucleic Acids Res 1997; 25: 3389-3402.